Results from the Phase III ADAURA clinical trial were announced at the virtual ASCO 2020 conference on Sunday 31 May, highlighting significant improvements in both primary and secondary endpoints, leading to a new standard of care for a subgroup of non-small-cell lung cancer (NSCLC) patients.
Last month, the ADAURA trial was recommended by an Independent Data Monitoring Committee (IDMC) to be unblinded two years early after detailed results and overwhelming efficacy were presented at ASCO 2020 for the first time. Read more here.
Go deeper with GlobalData
